Events
Registration now open for Eyes On Cataract & Refractive 2025
Virtual event offers up to 5 hours of free CME for MDs featuring rapid-fire videos, real-world case studies, and clinical expert-led interactive sessions.Research
Botox injections may actually help treat DED
Botox injections significantly improved key disease parameters, supporting its potential clinical utility.Products
CSI Dry Eye Software releases update for AI-based clinical platform
Version 6.0 of the cloud-based software features an intuitive dashboard and automated reminders for clinicians diagnosing and treating DED patients.Pipeline
Aldeyra resubmits reproxalap NDA for dry eye (again)
Company includes new phase 3 dry eye crossover data in updated submission package; an FDA acknowledgement response is expected within 30 days.Research
GLP-1 drug users twice as likely to develop nAMD
New research findings also report risk was 3 times as high among diabetic patients with the longest exposure to GLP-1 RAs.Events
Dry Eye Foundation to host DC advocacy days in July
Nonprofit prepares to kick off its first-ever dry eye patient advocacy day and symposium at the Capitol to raise awareness of the impact of DED on everyday lifeProducts
Glenmark launches olopatadine HCl 0.2% to US market
Generic version of Alcon’s Pataday Once Daily Relief eye drops temporarily relieves itchy eyes due to pollen, ragweed, animal hair, and dander.Pipeline
FDA clears Ocugen for phase 2/3 trial on Stargardt gene therapy
IND approval enables continued clinical evaluation of OCU410ST, a modifier gene therapy with a favorable safety and tolerability profile; plans include a 2027 BLA submission.Research
Study suggests toddlers’ eye movements predict their metamemory
Investigators demonstrate the ability to judge the reliability of our memories may develop as early as 2 years old.Products
FDA approves Amneal's prednisolone acetate ophthalmic suspension
Referencing Allergan's Pred Forte, this 1% concentrated drop is expected to hit the U.S. market by Q3 2025.Products
Ocubio introduces personalized autologous serum eye drops
Based on a proprietary manufacturing protocol from Bascom Palmer, qASED uses patients’ blood in the formulation to target the ocular surface.Research
Study ties magnesium to reduced RVO risk
Sufficient magnesium intake significantly reduced risk of RVO, particularly in three key subgroups.Products
Gore launches silicone-free syringe plunger for prefilled syringes
The 0.5 mL GORE IMPROJECT plunger is specially designed for use in various silicon-sensitive clinical applications—including IVT injections.Pipeline
Qlaris Bio developing fixed-dose latanoprost and QLS-111 eye drop for glaucoma
New combination therapy involving the prostaglandin analog targets lowering episcleral venous pressure to lower IOP.Pipeline
SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform
Financing to support upcoming phase 3 trials on the company’s long-term delivery system of bimatoprost for glaucoma and OHT treatment.Research
Does silicone oil cause macular edema post-RRD surgery?
Study identifies two key factors that may significantly increase the risk for macular edema development.Pipeline
FDA clears IND for Zhaoke Ophthalmology's CsA ophthalmic gel
Clearance paves the way for a new phase 3 trial to evaluate CsA 0.05% for its safety and efficacy among moderate-to-severe DED patients—with plans for an eventual NDA submission.Products
Coburn Technologies debuts the Huvitz HVS-1 Vision Screener
Handheld portable device assesses refractive errors in just 1 second, providing non-contact and precise measurements for pediatric and elderly patients.Products
Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain
Commercial rights for the newly-named BYQLOVI reportedly purchased from Formosa; plans include a Q4 2025 launch.Pipeline